Search

Redwood City-based CardioKinetix, the developer of transcatheter implants used to treat patients with heart failure, has raised $44M, the firm said, in a Series E financing round. The funding came via two tranches, and was led by SV Life Sciences and New Leaf Venture Partners. Other investors in the round included U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors. CardioKinetix is currently in clinical studies in Europe, and has FDA approvals for an IDE trial of its devices. Paul LaViolette of SV Life Sciences and Jeani Delagardelle at New Leaf have joined the firm's board with the funding.
posted on Thursday, September 22, 2011 (Link to more information)

Related companies:
CARDIOKINETIX

Related stories:
> CardioKinetix Scores $48M For Heart Failure Treatment

---

silicontap.com Home